A
Alcista
Alcista · 25%RNAZ
$12.58
Precio del escenario
$1.510
0.000 (0.00%)Al cierre
Loading chart…
- Máximo
- 1.560
- Apertura
- 1.530
- Precio medio ponderado por volumen
- 1.51
- Volumen
- 12.78K
- Capitalización
- 7.34M
- Mínimo
- 1.450
- Importe
- 19.25K
- EV/EBITDA, TTM
- 0.00
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Análisis de IA of Transcode Therapeutics Inc (RNAZ)
VenderTranscode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 25.149, indicating oversold conditions, and a staggering year-to-date change of -79.59%. The stock is currently trading at $1.51, significantly below its 52-week high of $12.60, which suggests a lack of investor confidence and potential for further declines. The main risk is its negative earnings trend, with a net income loss of -$19,510,296 in Q1 2026, which raises concerns about its financial viability.
Métricas de valoración
El PER previsto actual de Transcode Therapeutics Inc (RNAZ) es 0.00, frente a su media de 5 años de -1.97.
Escenarios de precio de Alphio AI para RNAZ
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
2.010-28PRnewswireTransCode Initiates Strategic Review to Enhance TTX-MC138 Value
2.010-28NewsfilterTransCode Initiates Strategic Review to Maximize Value of TTX-MC138
- 9.010-26Newsfilter
TransCode Presents Phase 1a Clinical Data for TTX-MC138
9.010-19PRnewswireTransCode to Present TTX-MC138 Clinical Updates at ESMO Congress 2026
8.510-13NewsfilterTransCode Partners with Natera to Advance Colorectal Cancer Clinical Trial
Preguntas frecuentes sobre RNAZ, respondidas por Alphio AI
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 25.149, indicating oversold conditions, and a staggering year-to-date change of -79.59%. The stock is currently trading at $1.51, significantly below its 52-week high of $12.60, which suggests a lack of investor confidence and potential for further declines. The main risk is its negative earnings trend, with a net income loss of -$19,510,296 in Q1 2026, which raises concerns about its financial viability.
Comunidad
Más ↗
After Hours Top Gainers PT2 $CRML $RNAZ $IPEX $RIBB $VRME
Mostrar másArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.